Literature DB >> 18829754

Role of Ebola virus VP30 in transcription reinitiation.

Miguel J Martínez1, Nadine Biedenkopf, Valentina Volchkova, Bettina Hartlieb, Nathalie Alazard-Dany, Olivier Reynard, Stephan Becker, Viktor Volchkov.   

Abstract

VP30 is a phosphoprotein essential for the initiation of Ebola virus transcription. In this work, we have studied the effect of mutations in VP30 phosphorylation sites on the ebolavirus replication cycle by using a reverse genetics system. We demonstrate that VP30 is involved in reinitiation of gene transcription and that this activity is affected by mutations at the phosphorylation sites.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18829754      PMCID： PMC2593317          DOI： 10.1128/JVI.01395-08

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  19 in total

Review 1.  Reverse genetics of mononegavirales.

Authors:  K K Conzelmann
Journal:  Curr Top Microbiol Immunol       Date:  2004       Impact factor: 4.291

Review 2.  Transcription and replication of nonsegmented negative-strand RNA viruses.

Authors:  S P J Whelan; J N Barr; G W Wertz
Journal:  Curr Top Microbiol Immunol       Date:  2004       Impact factor: 4.291

3.  Differentiation of filoviruses by electron microscopy.

Authors:  T W Geisbert; P B Jahrling
Journal:  Virus Res       Date:  1995-12       Impact factor: 3.303

Review 4.  Nonsegmented negative-strand RNA viruses: genetics and manipulation of viral genomes.

Authors:  K K Conzelmann
Journal:  Annu Rev Genet       Date:  1998       Impact factor: 16.830

5.  Termini of all mRNA species of Marburg virus: sequence and secondary structure.

Authors:  E Mühlberger; S Trommer; C Funke; V Volchkov; H D Klenk; S Becker
Journal:  Virology       Date:  1996-09-15       Impact factor: 3.616

6.  Descriptive analysis of Ebola virus proteins.

Authors:  L H Elliott; M P Kiley; J B McCormick
Journal:  Virology       Date:  1985-11       Impact factor: 3.616

7.  Ebola virus VP30-mediated transcription is regulated by RNA secondary structure formation.

Authors:  Michael Weik; Jens Modrof; Hans-Dieter Klenk; Stephan Becker; Elke Mühlberger
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

8.  Comparison of the transcription and replication strategies of marburg virus and Ebola virus by using artificial replication systems.

Authors:  E Mühlberger; M Weik; V E Volchkov; H D Klenk; S Becker
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

9.  Sequence analysis of the Ebola virus genome: organization, genetic elements, and comparison with the genome of Marburg virus.

Authors:  A Sanchez; M P Kiley; B P Holloway; D D Auperin
Journal:  Virus Res       Date:  1993-09       Impact factor: 3.303

10.  Phosphorylation of VP30 impairs ebola virus transcription.

Authors:  Jens Modrof; Elke Mühlberger; Hans-Dieter Klenk; Stephan Becker
Journal:  J Biol Chem       Date:  2002-06-06       Impact factor: 5.157
View more
  41 in total

1.  Recombinant Marburg virus expressing EGFP allows rapid screening of virus growth and real-time visualization of virus spread.

Authors:  Kristina Maria Schmidt; Michael Schümann; Judith Olejnik; Verena Krähling; Elke Mühlberger
Journal:  J Infect Dis       Date:  2011-11       Impact factor: 5.226

2.  Identification of essential filovirion-associated host factors by serial proteomic analysis and RNAi screen.

Authors:  Kevin B Spurgers; Tim Alefantis; Brian D Peyser; Gordon T Ruthel; Alison A Bergeron; Julie A Costantino; Sven Enterlein; Krishna P Kota; R C Dutch Boltz; M Javad Aman; Vito G Delvecchio; Sina Bavari
Journal:  Mol Cell Proteomics       Date:  2010-08-11       Impact factor: 5.911

3.  Predictive and comparative analysis of Ebolavirus proteins.

Authors:  Qian Cong; Jimin Pei; Nick V Grishin
Journal:  Cell Cycle       Date:  2015-07-09       Impact factor: 4.534

4.  RNA Binding of Ebola Virus VP30 Is Essential for Activating Viral Transcription.

Authors:  Nadine Biedenkopf; Julia Schlereth; Arnold Grünweller; Stephan Becker; Roland K Hartmann
Journal:  J Virol       Date:  2016-07-27       Impact factor: 5.103

5.  Ebolavirus VP24 binding to karyopherins is required for inhibition of interferon signaling.

Authors:  Mathieu Mateo; St Patrick Reid; Lawrence W Leung; Christopher F Basler; Viktor E Volchkov
Journal:  J Virol       Date:  2009-11-04       Impact factor: 5.103

6.  Phosphorylation of Ebola virus VP30 influences the composition of the viral nucleocapsid complex: impact on viral transcription and replication.

Authors:  Nadine Biedenkopf; Bettina Hartlieb; Thomas Hoenen; Stephan Becker
Journal:  J Biol Chem       Date:  2013-03-14       Impact factor: 5.157

7.  The L-VP35 and L-L interaction domains reside in the amino terminus of the Ebola virus L protein and are potential targets for antivirals.

Authors:  Martina Trunschke; Dominik Conrad; Sven Enterlein; Judith Olejnik; Kristina Brauburger; Elke Mühlberger
Journal:  Virology       Date:  2013-04-11       Impact factor: 3.616

8.  Role of protein phosphatase 1 in dephosphorylation of Ebola virus VP30 protein and its targeting for the inhibition of viral transcription.

Authors:  Philipp A Ilinykh; Bersabeh Tigabu; Andrey Ivanov; Tatiana Ammosova; Yuri Obukhov; Tania Garron; Namita Kumari; Dmytro Kovalskyy; Maxim O Platonov; Vasiliy S Naumchik; Alexander N Freiberg; Sergei Nekhai; Alexander Bukreyev
Journal:  J Biol Chem       Date:  2014-06-16       Impact factor: 5.157

Review 9.  Development and application of reporter-expressing mononegaviruses: current challenges and perspectives.

Authors:  Darryl Falzarano; Allison Groseth; Thomas Hoenen
Journal:  Antiviral Res       Date:  2014-01-23       Impact factor: 5.970

10.  Mutations abrogating VP35 interaction with double-stranded RNA render Ebola virus avirulent in guinea pigs.

Authors:  Kathleen C Prins; Sebastien Delpeut; Daisy W Leung; Olivier Reynard; Valentina A Volchkova; St Patrick Reid; Parameshwaran Ramanan; Washington B Cárdenas; Gaya K Amarasinghe; Viktor E Volchkov; Christopher F Basler
Journal:  J Virol       Date:  2010-01-13       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.